Program
Lenalidomide
Also written as “lenalidomide”, “CC-5013” and “Drug: Carfilzomib + Lenalidomide + Dexamethasone”.
Its studies are mostly in Multiple Myeloma · Lymphoma, Large B-Cell, Diffuse · Myelodysplastic Syndromes · Lymphoma, Non-Hodgkin · Lymphoma, Mantle-Cell, led by 6 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 670 open or running | phase 3since Mar 5, 2003 | Aug 16, 2002 | none ahead |
| Takeda | 50 open or running | phase 4since May 30, 2017 | Jul 25, 2007 | none ahead |
| Oncotherapeutics | 32 open or running | phase 2since Jul 30, 2014 | Jul 30, 2014 | none ahead |
| bionor-immuno-as | 10 open or running | phase 2since Sep 11, 2012 | Sep 11, 2012 | none ahead |
| Samyang Biopharmaceuticals | 10 open or running | phase 1since Jun 25, 2017 | Jun 25, 2017 | none ahead |
| starton-therapeutics-inc | 11 open or running | phase 2since Sep 20, 2023 | Sep 20, 2023 | May 31, 2027phase 2 · NCT06087653 |
Also a collaborator on its studies: AbbVie, prologue-research-international, Karyopharm Therapeutics, Incyte, Johnson & Johnson, Abbott, icon-clinical-research and Hoffmann-La Roche.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Sep 10, 2005.
- Nov 4, 2014Phase 3 study in Lymphoma, Large B-Cell, DiffuseBristol-Myers Squibb · NCT02285062 · 570 enrolled · United States, Australia, Belgium and more
- Jan 23, 2015Phase 2 study in Multiple MyelomaBristol-Myers Squibb · NCT02348528 · 65 enrolled · China
- Aug 11, 2015Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT02521714 · 28 enrolled · United States
- Aug 25, 2015Phase 2 study in Leukemia, MyeloidBristol-Myers Squibb · NCT02538965 · 17 enrolled · United States, Canada
- Feb 16, 2016Phase 2 study in Multiple MyelomaBristol-Myers Squibb · NCT02685826 · 56 enrolled · United States, Canada, Denmark and more
- Sep 22, 2016Phase 2 study in Relapsed and/or Refractory Multiple MyelomaTakeda · NCT02917941 · 34 enrolled · Japan
- Feb 27, 2017Phase 1 study in Multiple MyelomaOncotherapeutics · NCT03110822 · 134 planned · United States
- May 30, 2017Phase 4 study in Multiple MyelomaTakeda · NCT03173092 · 141 enrolled · United States
- Jun 25, 2017Samyang Biopharmaceuticals's first study: phase 1 study in Healthy, MaleNew to Samyang BiopharmaceuticalsSamyang Biopharmaceuticals · NCT03208218 · 42 enrolled
- Jan 23, 2018Phase 4 study in Relapsed and/or Refractory Multiple MyelomaTakeda · NCT03416374 · 45 enrolled · Japan
- Aug 16, 2018Phase 3 study in Multiple MyelomaBristol-Myers Squibb · NCT03651128 · 386 enrolled · United States, Belgium, Canada and more
- Aug 12, 2020Phase 1 study in Multiple MyelomaOncotherapeutics · NCT04519476 · 22 planned · United States
- Dec 20, 2021Phase 4 study in Multiple MyelomaTakeda · NCT05183139
- Sep 20, 2023starton-therapeutics-inc's first study: phase 2 study in Multiple MyelomaNew to starton-therapeutics-incstarton-therapeutics-inc · NCT06087653 · 24 planned · United States
Ahead
- May 31, 2027Primary completion: phase 2 study in Multiple Myelomastarton-therapeutics-inc · NCT06087653
TargetBeta
“CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| pomalidomiderule | Bristol-Myers Squibb | phase 4 | 51 |
Studies
The newest 60 of 78 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06087653Multiple Myeloma · United States | 2 | Recruiting | starton-therapeutics-inc | May 31, 2027 | 24 |
| NCT05183139Multiple Myeloma | 4 | Withdrawn | Takeda | Dec 31, 2026 | 0 |
| NCT04519476Multiple Myeloma · United States | 1 | Recruiting | Oncotherapeutics | Dec 29, 2023 | 22 |
| NCT03651128Multiple Myeloma · United States, Belgium, Canada and more | 3 | Completed | Bristol-Myers Squibb | Apr 13, 2026 | 386 |
| NCT03416374Relapsed and/or Refractory Multiple Myeloma · Japan | 4 | Completed | Takeda | May 28, 2021 | 45 |
| NCT03208218Healthy, Male | 1 | Completed | Samyang Biopharmaceuticals | Aug 25, 2016 | 42 |
| NCT03173092Multiple Myeloma · United States | 4 | Terminated | Takeda | Mar 30, 2026 | 141 |
| NCT03110822Multiple Myeloma · United States | 1 | Recruiting | Oncotherapeutics | Sep 2024 | 134 |
| NCT02917941Relapsed and/or Refractory Multiple Myeloma · Japan | 2 | Completed | Takeda | Aug 31, 2019 | 34 |
| NCT02685826Multiple Myeloma · United States, Canada, Denmark and more | 2 | Completed | Bristol-Myers Squibb | Dec 15, 2017 | 56 |
| NCT02538965Leukemia, Myeloid · United States, Canada | 2 | Completed | Bristol-Myers Squibb | Jul 22, 2017 | 17 |
| NCT02521714Healthy Volunteers · United States | 1 | Completed | Bristol-Myers Squibb | Sep 23, 2015 | 28 |
| NCT02348528Multiple Myeloma · China | 2 | Completed | Bristol-Myers Squibb | Sep 29, 2016 | 65 |
| NCT02285062Lymphoma, Large B-Cell, Diffuse · United States, Australia, Belgium and more | 3 | Completed | Bristol-Myers Squibb | Mar 15, 2019 | 570 |
| NCT02206425Multiple Myeloma · United States | 2 | Completed | Oncotherapeutics | Jan 19, 2018 | 45 |
| NCT02155634Multiple Myeloma | 3 | Withdrawn | Bristol-Myers Squibb | Apr 2017 | 0 |
| NCT02112175Multiple Myeloma · Belgium, France, Greece and more | 3 | Completed | Bristol-Myers Squibb | Oct 12, 2020 | 46 |
| NCT01996865Lymphoma, Non-Hodgkin · United States, Germany, Puerto Rico | 3 | Completed | Bristol-Myers Squibb | May 11, 2024 | 503 |
| NCT01938001Lymphoma, Non-Hodgkin · United States, Belgium, Brazil and more | 3 | Completed | Bristol-Myers Squibb | Jun 22, 2018 | 358 |
| NCT01891643Newly Diagnosed, Previously Untreated Multiple Myeloma · United States, Greece, Italy and more | 3 | Terminated | Bristol-Myers Squibb | Jun 25, 2020 | 23 |
| NCT01724177Leukemia-Lymphoma, Adult T-Cell · Japan | 2 | Completed | Bristol-Myers Squibb | Nov 20, 2014 | 26 |
| NCT01698801Multiple Myeloma · Japan | 2 | Completed | Bristol-Myers Squibb | Nov 26, 2013 | 26 |
| NCT01704781Infections · Germany | 2 | Completed | bionor-immuno-as | Aug 2014 | 36 |
| NCT01593410Multiple Myeloma · China | 2 | Completed | Bristol-Myers Squibb | Jan 3, 2013 | 194 |
| NCT01476787Lymphoma, Follicular · United States, Japan | 3 | Completed | Bristol-Myers Squibb | Apr 30, 2024 | 1,030 |
| NCT01358734Leukemia, Myeloid, Acute · United States, Canada | 2 | Completed | Bristol-Myers Squibb | May 19, 2015 | 88 |
| NCT01197560Lymphoma, Large B-Cell, Diffuse · United States, Australia, Austria and more | 3 | Completed | Bristol-Myers Squibb | Jul 4, 2013 | 111 |
| NCT01169298Leukemia-Lymphoma, Adult T-Cell · Japan | 1 | Completed | Bristol-Myers Squibb | Dec 1, 2013 | 13 |
| NCT01032291Colorectal Neoplasms · Australia, Belgium, Germany and more | 2 | Terminated | Bristol-Myers Squibb | Jan 2011 | 51 |
| NCT01029262Anemia · United States, Australia, Austria and more | 3 | Completed | Bristol-Myers Squibb | Mar 17, 2013 | 239 |
| NCT01021423Lymphoma, Mantle-Cell · United States, Czechia, France and more | 3 | Terminated | Bristol-Myers Squibb | Mar 1, 2011 | 9 |
| NCT00988208Prostatic Neoplasms · United States, Australia, Austria and more | 3 | Completed | Bristol-Myers Squibb | Jan 13, 2012 | 1,059 |
| NCT00975806Carcinoma, Renal Cell · United States | 2 | Terminated | Bristol-Myers Squibb | Oct 1, 2011 | 16 |
| NCT00963105Recurrence · United States, Canada, France and more | 2 | Completed | Bristol-Myers Squibb | Sep 5, 2017 | 104 |
| NCT00928486Multiple Myeloma · Japan | 3 | Completed | Bristol-Myers Squibb | Sep 10, 2010 | 25 |
| NCT00910910Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 3 | Completed | Bristol-Myers Squibb | Mar 31, 2014 | 450 |
| NCT00910858Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS) · United States | 2 | Completed | Bristol-Myers Squibb | Apr 2006 | 40 |
| NCT00875667Lymphoma, Mantle-Cell · Belgium, Czechia, Denmark and more | 2 | Completed | Bristol-Myers Squibb | Jun 28, 2018 | 254 |
| NCT00812968Myelodysplastic Syndromes · Japan | 2 | Completed | Bristol-Myers Squibb | Sep 1, 2010 | 11 |
| NCT00774345Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 3 | Completed | Bristol-Myers Squibb | Oct 27, 2020 | 317 |
| NCT00737529Lymphoma, Mantle-Cell · United States, Austria, Belgium and more | 2 | Completed | Bristol-Myers Squibb | Apr 6, 2016 | 134 |
| NCT00689936Multiple Myeloma · United States, Australia, Austria and more | 3 | Completed | Bristol-Myers Squibb | Jul 14, 2016 | 1,623 |
| NCT00655668Lymphoma, T-Cell · United States, Australia, Belgium and more | 2 | Terminated | Bristol-Myers Squibb | Mar 1, 2010 | 54 |
| NCT00622336Multiple Myeloma · Russian Federation, Ukraine | 3 | Completed | Bristol-Myers Squibb | Nov 25, 2013 | 330 |
| NCT00555100Multiple Myeloma · Japan | 1 | Completed | Bristol-Myers Squibb | Dec 1, 2010 | 15 |
| NCT00507442Multiple Myeloma · United States | 2 | Completed | Takeda | Oct 2010 | 158 |
| NCT00478777Recurrence · Germany | 3 | Completed | Bristol-Myers Squibb | Nov 2007 | 150 |
| NCT00474188Lymphoma, Large B-Cell, Diffuse · United States, Australia, Canada | 2 | Terminated | Bristol-Myers Squibb | Dec 2008 | 26 |
| NCT00446433Crohn Disease · United States, France, Israel and more | 2 | Completed | Bristol-Myers Squibb | 90 | |
| NCT00424047Multiple Myeloma · Australia, Austria, Belgium and more | 3 | Completed | Bristol-Myers Squibb | Nov 1, 2005 | 351 |
| NCT00420849Multiple Myeloma · Australia, Austria, Ireland and more | 3 | Completed | Bristol-Myers Squibb | Oct 2009 | 587 |
| NCT00419250Leukemia, Lymphocytic, Chronic, B-Cell · United States, Canada, Germany and more | 1 | Completed | Bristol-Myers Squibb | Feb 1, 2010 | 52 |
| NCT00413036Lymphoma, Non-Hodgkin · United States, Canada, France and more | 2 | Completed | Bristol-Myers Squibb | Apr 2011 | 217 |
| NCT00405756Newly Diagnosed Multiple Myeloma · Australia, Austria, Belarus and more | 3 | Completed | Bristol-Myers Squibb | Nov 2009 | 459 |
| NCT00179751Pancreatic Neoplasms · United States | 2 | Terminated | Bristol-Myers Squibb | 50 | |
| NCT00179738Prostatic Neoplasms · United States | 2 | Terminated | Bristol-Myers Squibb | 40 | |
| NCT00179725Ovarian Neoplasms · United States | 2 | Terminated | Bristol-Myers Squibb | 60 | |
| NCT00179712Ovarian Neoplasms · United States | 2 | Completed | Bristol-Myers Squibb | 60 | |
| NCT00179699Carcinoma, Non-Small-Cell Lung · United States | 1 | Terminated | Bristol-Myers Squibb | 40 | |
| NCT00179686Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Bristol-Myers Squibb | 40 |
How it is read
Names in the registry
- “Lenalidomide”, 67 entries
- “lenalidomide”, 16 entries
- “CC-5013”, 14 entries
- “Drug: Carfilzomib + Lenalidomide + Dexamethasone”, 1 entry
- “Tafasitamab plus lenalidomide”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 45 studies
- Lymphoma, Large B-Cell, Diffuse, 10 studies
- Myelodysplastic Syndromes, 8 studies
- Lymphoma, Non-Hodgkin, 5 studies
- Lymphoma, Mantle-Cell, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.